Dantron
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
| 1,8-dihydroxyanthracene-9,10-dione | |
| Identifiers | |
| CAS number | 117-10-2 |
| ATC code | A06AB03 A06AB53 A06AG03 |
| PubChem | 2950 |
| ChemSpider | 2845 |
| Chemical data | |
| Formula | C14H8O4 |
| Mol. mass | 240.211 g/mol |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral, rectal (enema) |
 (what is this?) (verify) |
|
- "Dantron" is also a trade name of ondansetron, an unrelated drug, in South Africa.
Dantron (also known as chrysazin) is an anthraquinone derivative, 1,8-dihydroxyanthraquinone, used in some countries as a stimulant laxative. In the USA it is considered to be a carcinogen,[1] and is therefore not used. In the UK it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer (i.e. it is mainly used in palliative care to counteract the constipating effects of opioids)
It has the notable side-effect of causing red-coloured urine.
Danthron was the British Approved Name, but it has now been changed to "dantron" in harmony with the recommended International Nonproprietary Name (rINN).
[edit] References
- ^ Danthron substance profile at the National Toxicology Program website
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||
